Drugs / TERN-701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06163430 | Mar 2024 → Nov 2029 expected | chronic myeloid leukemia | Terns, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-25 | Merck Sharp & Dohme LLC | MSD to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) msd.com ↗ |
| 2026-03-25 | Merck Sharp & Dohme LLC | Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TERN-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06163430 ↗ |
| Action | Inhibit | “allosteric inhibitor of BCR-ABL1” NCT06163430 ↗ |
| Route | Oral | “TERN-701 orally QD” NCT06163430 ↗ |